Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
A clinical study, carried out in different centers and using a placebo, to assess the effect of a medicinal product, containing sapropterin as the active substance, on mental abilities in young adults suffering from phenylketonuria, a genetic disease in which an enzyme defect leads to accumulation of a waste product (phenylketone) which can be detected in urine
The purpose of this pilot trial is to assess the effect of sapropterin on the cognitive abilities of young adults with phenylketonuria (PKU).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
Update Il y a 5 ans
A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)
The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in preventing new flares in subjects with SLE.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA (Germany)
Update Il y a 5 ans
A multinational, multicenter, open-label, controlled, randomised, parallel group study to evaluate the efficacy and safety of EMD 121974 and gemcitabine or gemcitabine alone in patients with advanced, unresectable pancreatic cancer
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis
The primary objective of the trial is to evaluate the effects of ATX-MS-1467 administered intradermally, titrated to a dose of 800 μg every 2 weeks (biweekly), for a total period of 20 weeks on 1.5T M...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 5 ans
Étude EMR 100070-005 : étude de phase 3 comparant l’avélumab avec un doublet à base de platine comme traitement de première ligne chez des patients ayant un cancer de poumon non à petites cellules récurrent ou de stade IV et positif pour PD-L1. [essai clos aux inclusions]
Le cancer de poumon non à petites cellules est le type de cancer de poumon le plus fréquent, qui représente 85-90% de l’ensemble des cancers de poumon. Les traitements principaux du cancer du poumon n...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing advanced NSCLC
To show superiority in terms of overall survival time of patients receiving platinum-based chemotherapy plus cetuximab as first-line treatment compared with patients receiving the same chemotherapy al...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
To compare overall survival (OS) time by treatment arm.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis
To assess the efficacy of M2951 in subjects with active RA on stable MTX therapy, as measured by the American College of Rheumatology (ACR) 20% (ACR20) response rate over a duration of 84 days.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)
Phase Ib To determine the RP2D of tepotinib when used in combination with gefitinib (at the approved standard dose of 250 mg) when administered orally once daily over a 21-day cycle in subjects wit...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 5 ans
Exploration if Saizen marketed solution for injection induces an immunogenic reaction
To determine whether the marketed Saizen solution for injection, administered according to the approved label for 9 months (39 weeks) in adults with GHD, induces the development of binding antibodies ...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
7
Next